A pathway activity-based proteomic classifier stratifies prostate tumors into two subtypes,Clinical Proteomics

当前位置： X-MOL 学术 › Clin. Proteom. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A pathway activity-based proteomic classifier stratifies prostate tumors into two subtypes
Clinical Proteomics ( IF 3.8 ) Pub Date : 2023-11-11 , DOI: 10.1186/s12014-023-09441-w
Rui Sun _{1,

2,

3} , Lingling Tan ₄ , Xuan Ding _{1,

2,

3} , Jun A _{1,

2,

3} , Zhangzhi Xue _{1,

2,

3} , Xue Cai _{1,

2,

3} , Sainan Li _{1,

2,

3} , Tiannan Guo _{1,

2,

3}

Affiliation

Prostate cancer (PCa) is the second most common cancer in males worldwide. The risk stratification of PCa is mainly based on morphological examination. Here we analyzed the proteome of 667 tumor samples from 487 Chinese PCa patients and characterized 9576 protein groups by PulseDIA mass spectrometry. Then we developed a pathway activity-based classifier concerning 13 proteins from seven pathways, and dichotomized the PCa patients into two subtypes, namely PPS1 and PPS2. PPS1 is featured with enhanced innate immunity, while PPS2 with suppressed innate immunity. This classifier exhibited a correlation with PCa progression in our cohort and was further validated by two published transcriptome datasets. Notably, PPS2 was significantly correlated with poor biochemical recurrence (BCR)/metastasis-free survival (log-rank P-value < 0.05). The PPS2 was also featured with cell proliferation activation. Together, our study presents a novel pathway activity-based stratification scheme for PCa.

更新日期：2023-11-11

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>